Abstract

The Emory ACE Fund Management Core (EAFMC) at Emory University proposes to manage on behalf of the ACE network two funds. The first will be the Clinical Project Fund, which will support all of the Clinical Projects (ClinProj) within the ACE. The second will be the Collaborative Research Fund (CRF). The CRF will provide funding support for the Collaborative Projects of the ACE, as well as additional studies that are added for achieving the ACE research agenda. It is estimated from the RFA that the AFMC will manage $3.2M in direct costs associated with these projects and that these will occur through about 100 consortium agreements emanating from up to 50 different sites. It will accomplish this through the following aims: (1) Establishing an effective administrative structure and operating unit, (2) developing plans to effectively produce and execute budgets and consortium agreements, (3) establish templates for the ClinProj and CRP budget agreements, (4) develop procedures to pay invoices and resolve problems; and (5) develop procedures for accountability, communication, and reporting to the ACE Steering committee and NIAID.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
2U19AI110483-06
Application #
9731111
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2019-05-01
Budget End
2020-04-30
Support Year
6
Fiscal Year
2019
Total Cost
Indirect Cost

  Institution

Name
Emory University
Department
Type
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322

  Publications

St Clair, E William; Baer, Alan N; Wei, Chungwen et al. (2018) Clinical Efficacy and Safety of Baminercept, a Lymphotoxin ? Receptor Fusion Protein, in Primary Sjögren's Syndrome: Results From a Phase II Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol 70:1470-1480
Tipton, Christopher M; Hom, Jennifer R; Fucile, Christopher F et al. (2018) Understanding B-cell activation and autoantibody repertoire selection in systemic lupus erythematosus: A B-cell immunomics approach. Immunol Rev 284:120-131
Putterman, Chaim; Pisetsky, David S; Petri, Michelle et al. (2018) The SLE-key test serological signature: new insights into the course of lupus. Rheumatology (Oxford) 57:1632-1640
Upadhyay, Amit A; Kauffman, Robert C; Wolabaugh, Amber N et al. (2018) BALDR: a computational pipeline for paired heavy and light chain immunoglobulin reconstruction in single-cell RNA-seq data. Genome Med 10:20
Jenks, Scott A; Cashman, Kevin S; Zumaquero, Esther et al. (2018) Distinct Effector B Cells Induced by Unregulated Toll-like Receptor 7 Contribute to Pathogenic Responses in Systemic Lupus Erythematosus. Immunity 49:725-739.e6
Hamilton, Jennie A; Wu, Qi; Yang, PingAr et al. (2018) Cutting Edge: Intracellular IFN-? and Distinct Type I IFN Expression Patterns in Circulating Systemic Lupus Erythematosus B Cells. J Immunol 201:2203-2208
Barwick, Benjamin G; Scharer, Christopher D; Martinez, Ryan J et al. (2018) B cell activation and plasma cell differentiation are inhibited by de novo DNA methylation. Nat Commun 9:1900
Asare, A; Kanaparthi, S; Lim, N et al. (2017) B Cell Receptor Genes Associated With Tolerance Identify a Cohort of Immunosuppressed Patients With Improved Renal Allograft Graft Function. Am J Transplant 17:2627-2639
Fortner, Karen A; Bond, Jeffrey P; Austin, James W et al. (2017) The molecular signature of murine T cell homeostatic proliferation reveals both inflammatory and immune inhibition patterns. J Autoimmun 82:47-61
Sanz, Iñaki (2017) New Perspectives in Rheumatology: May You Live in Interesting Times: Challenges and Opportunities in Lupus Research. Arthritis Rheumatol 69:1552-1559

Showing the most recent 10 out of 33 publications